ETOP 9-15: PROMISE-meso: PembROlizuMab Immunotherapy versus Standard chemotherapy for advanced prEtreated malignant pleural mesothelioma: A multicentre randomised phase III study comparing pembrolizumab versus standard chemotherapy for advanced pretreated malignant pleural mesothelioma/ EORTC 08112 (NEMO): Nintedanib as maintenance treatment of pleural malignant mesothelioma: a randomized phase II study of the EORTC Lung Cancer Group